{"protocolSection": {"identificationModule": {"nctId": "NCT00712673", "orgStudyIdInfo": {"id": "EFC6014"}, "secondaryIdInfos": [{"id": "EudraCT 2007-005880-80"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin", "acronym": "GETGOAL-M"}, "statusModule": {"statusVerifiedDate": "2016-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-06"}, "primaryCompletionDateStruct": {"date": "2011-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-07-07", "studyFirstSubmitQcDate": "2008-07-07", "studyFirstPostDateStruct": {"date": "2008-07-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-08-18", "resultsFirstSubmitQcDate": "2016-10-24", "resultsFirstPostDateStruct": {"date": "2016-12-15", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-04-13", "dispFirstSubmitQcDate": "2012-04-13", "dispFirstPostDateStruct": {"date": "2012-04-16", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-10-24", "lastUpdatePostDateStruct": {"date": "2016-12-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide as an add-on treatment to metformin in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effect of lixisenatide, in comparison to placebo, when administered in the evening within 1 hour prior to the meal in terms of HbA1c reduction, percentage of patients reaching HbA1c less than (\\<) 7 percent (%), percentage of patients reaching HbA1c less than or equal to 6.5%, fasting plasma glucose (FPG), plasma glucose, plasma insulin, C-peptide, glucagon, and proinsulin during a 2-hour standardized meal test (only in morning injection arms), body weight, beta-cell function assessed by homeostasis model assessment (HOMA)-beta, fasting plasma insulin (FPI) and adiponectin; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development, beta-cell function 4 weeks after study drug discontinuation (only in patients from the morning injection arms in some selected centers).", "detailedDescription": "Patients who complete the 24-week main double-blind treatment would undergo a variable double-blind extension treatment, which ends for all patients at approximately the scheduled date of Week 76 visit (Visit 25) for the last randomized patient."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["hyperglycemia, GLP-1, metformin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 680, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lixisenatide (Morning Injection)", "type": "EXPERIMENTAL", "description": "2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.", "interventionNames": ["Drug: Lixisenatide (AVE0010)", "Device: Pen auto-injector", "Drug: Metformin"]}, {"label": "Lixisenatide (Evening Injection)", "type": "EXPERIMENTAL", "description": "2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.", "interventionNames": ["Drug: Lixisenatide (AVE0010)", "Device: Pen auto-injector", "Drug: Metformin"]}, {"label": "Placebo (Morning Injection)", "type": "PLACEBO_COMPARATOR", "description": "2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.", "interventionNames": ["Drug: Placebo", "Device: Pen auto-injector", "Drug: Metformin"]}, {"label": "Placebo (Evening Injection)", "type": "PLACEBO_COMPARATOR", "description": "2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.", "interventionNames": ["Drug: Placebo", "Device: Pen auto-injector", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Lixisenatide (AVE0010)", "description": "Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).", "armGroupLabels": ["Lixisenatide (Evening Injection)", "Lixisenatide (Morning Injection)"]}, {"type": "DRUG", "name": "Placebo", "description": "Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).", "armGroupLabels": ["Placebo (Evening Injection)", "Placebo (Morning Injection)"]}, {"type": "DEVICE", "name": "Pen auto-injector", "armGroupLabels": ["Lixisenatide (Evening Injection)", "Lixisenatide (Morning Injection)", "Placebo (Evening Injection)", "Placebo (Morning Injection)"], "otherNames": ["OptiClik\u00ae"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.", "armGroupLabels": ["Lixisenatide (Evening Injection)", "Lixisenatide (Morning Injection)", "Placebo (Evening Injection)", "Placebo (Morning Injection)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in 2-Hour Postprandial Plasma Insulin (PPI) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Proinsulin at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in 2-Hour Postprandial Proinsulin at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting C-Peptide at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in 2-Hour Postprandial C-Peptide at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Glucagon at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in 2-Hour Postprandial Glucagon at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Adiponectin at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24", "description": "Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (FPG \\[mmol/L\\] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients Requiring Rescue Therapy During the Main 24-Week Period", "description": "Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline up to Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}, {"measure": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Week 24"}], "otherOutcomes": [{"measure": "Change From Baseline in Glucose Excursion at Week 24", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "timeFrame": "Baseline, Week 24"}, {"measure": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "timeFrame": "First dose of study drug up to 3 days after the last dose administration"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 gram/ day (g/day) for at least 3 months prior to screening visit\n\nExclusion Criteria:\n\n* HbA1c \\<7% or greater than (\\>) 10% at screening\n* At the time of screening age \\< legal age of majority\n* Pregnant or breastfeeding women or women of childbearing potential with no effective contraceptive method\n* Type 1 diabetes mellitus\n* Treatment with an antidiabetic pharmacological agent other than metformin within the 3 months preceding the screening\n* FPG at screening \\>250 milligram per deciliter (mg/dL) (\\>13.9 millimole per liter \\[mmol/L\\])\n* Body mass index (BMI) \\<=20 kilogram per square meter (kg/m\\^2)\n* Weight change of \\>5 kg during the 3 months preceding the study screening visit\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease\n* History of metabolic acidosis, including diabetic ketoacidosis, within 1 year prior to screening\n* Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening\n* Within the last 6 months prior to screening, history of myocardial infarction, stroke, or heart failure requiring hospitalization\n* Known history of drug or alcohol abuse within 6 months prior to the time of screening\n* Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period\n* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic blood pressure or diastolic blood pressure \\>180 millimeter of mercury (mmHg) or \\>95 mmHg, respectively\n* Laboratory findings at the time of screening: aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase: \\>2 times upper limit of normal (ULN) laboratory range; amylase and/or lipase: \\>3 times ULN; total bilirubin: \\>1.5 times ULN (except in case of Gilbert's syndrome); Hemoglobin \\<11 gram/deciliter and/or neutrophils \\<1500 per cubic millimeter (mm\\^3) and/or platelets \\<100 000/mm\\^3; positive test for Hepatitis B surface antigen and/or Hepatitis C antibody; positive serum pregnancy test in females of child bearing potential\n* Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram, or vital signs at the time of screening that, in the judgment of the investigator or any sub-investigator, precludes safe completion of the study or constrains efficacy assessment\n* Patients who are considered by the investigator or any sub-investigator as inappropriate for this study for any reason (for example, impossibility to meet specific protocol requirements \\[such as scheduled visits, being able to do self-injections\\]; likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol; investigator or any sub-investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol)\n* Use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin (for example, sulfonylurea, alpha glucosidase inhibitor, other thiazolidinediones, rimonabant, exenatide, dipeptidyl-peptidase-4 inhibitors, insulin) within 3 months prior to the time of screening\n* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to the time of screening\n* Use of any investigational drug within 3 months prior to study\n* Any previous treatment with lixisenatide or participation in a previous study with lixisenatide\n* Renal impairment defined with creatinine \\>1.4 mg/dL in women and creatinine \\>1.5 mg/dL in men\n* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to, gastroparesis and gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening\n* Allergic reaction to any glucagon-like peptide-1(GLP-1) agonist in the past (for example, exenatide, liraglutide) or to metacresol\n* Additional exclusion criteria at the end of the run-in phase: informed consent withdrawal; lack of compliance during the single-blind placebo run-in phase (\\>2 injections missed); and patient with any adverse event which precludes the inclusion in the study, as assessed by the investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sanofi-Aventis Administrative Office", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "sanofi-aventis Australia & New Zealand administrative office", "city": "Macquarie Park", "country": "Australia", "geoPoint": {"lat": -33.7751, "lon": 151.11272}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Laval", "country": "Canada", "geoPoint": {"lat": 45.56995, "lon": -73.692}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Zagreb", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Casablanca", "country": "Morocco", "geoPoint": {"lat": 33.58831, "lon": -7.61138}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Makati City", "country": "Philippines", "geoPoint": {"lat": 14.55027, "lon": 121.03269}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Bucuresti", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Midrand", "country": "South Africa", "geoPoint": {"lat": -25.98953, "lon": 28.12843}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Caracas", "country": "Venezuela", "geoPoint": {"lat": 10.48801, "lon": -66.87919}}]}, "referencesModule": {"references": [{"pmid": "23536584", "type": "RESULT", "citation": "Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013 Sep;36(9):2543-50. doi: 10.2337/dc12-2006. Epub 2013 Mar 27."}, {"pmid": "27319011", "type": "DERIVED", "citation": "Ahren B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Sep;7(3):583-90. doi: 10.1007/s13300-016-0179-6. Epub 2016 Jun 18."}, {"pmid": "27267268", "type": "DERIVED", "citation": "Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, Gonzalez-Galvez G, Lin J, Nikonova EV, de Pablos-Velasco P, Yale JF, Ahren B. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse beta-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016 Sep-Oct;30(7):1385-92. doi: 10.1016/j.jdiacomp.2016.05.018. Epub 2016 May 24."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 1374 patients were screened of which 694 (50.5%) were screen failures; main reason for screen failure was glycosylated hemoglobin (HbA1c) values being out of the defined protocol range (greater than or equal to 7% and less than or equal to 10%). A total of 680 patients were randomized.", "recruitmentDetails": "The study was conducted at 133 centers in 16 countries between June 30, 2008 and March 09, 2011. The overall duration of treatment was at least 76 weeks (24 weeks main double-blind treatment; variable double-blind extension treatment).", "groups": [{"id": "FG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."}, {"id": "FG001", "title": "Placebo (Evening Injection)", "description": "2-step initiation evening regimen of volume matching placebo: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."}, {"id": "FG002", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."}, {"id": "FG003", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized.", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "85"}, {"groupId": "FG002", "numSubjects": "255"}, {"groupId": "FG003", "numSubjects": "255"}]}, {"type": "Safety Population", "achievements": [{"groupId": "FG000", "comment": "All patients who were exposed to at least 1 dose, regardless of amount of treatment administered.", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "85"}, {"groupId": "FG002", "numSubjects": "255"}, {"groupId": "FG003", "numSubjects": "255"}]}, {"type": "Modified Intent-to-Treat(mITT)Population", "achievements": [{"groupId": "FG000", "comment": "All patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment.", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "85"}, {"groupId": "FG002", "numSubjects": "255"}, {"groupId": "FG003", "numSubjects": "255"}]}, {"type": "Subgroup for Standardized Meal Test", "achievements": [{"groupId": "FG000", "comment": "Patients from morning injection arms where standardized meal test was performed.", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "255"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "64"}, {"groupId": "FG001", "numSubjects": "64"}, {"groupId": "FG002", "numSubjects": "198"}, {"groupId": "FG003", "numSubjects": "185"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "57"}, {"groupId": "FG003", "numSubjects": "70"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "21"}, {"groupId": "FG003", "numSubjects": "26"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "Poor Compliance to Protocol", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "20"}]}, {"type": "Familial and Personal Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Investigator's Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "groups": [{"id": "BG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "BG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."}, {"id": "BG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide: 10 mcg QD subcutaneously for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "255"}, {"groupId": "BG002", "value": "255"}, {"groupId": "BG003", "value": "680"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.0", "spread": "9.4"}, {"groupId": "BG001", "value": "54.5", "spread": "9.2"}, {"groupId": "BG002", "value": "54.8", "spread": "10.4"}, {"groupId": "BG003", "value": "54.7", "spread": "9.7"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "157"}, {"groupId": "BG002", "value": "141"}, {"groupId": "BG003", "value": "387"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "114"}, {"groupId": "BG003", "value": "293"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Race: Caucasian/White", "categories": [{"measurements": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "221"}, {"groupId": "BG002", "value": "228"}, {"groupId": "BG003", "value": "604"}]}]}, {"title": "Race: Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "17"}]}]}, {"title": "Race: Asian/Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "20"}, {"groupId": "BG003", "value": "53"}]}]}, {"title": "Race: Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}]}]}, {"title": "Ethnicity: Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "98"}, {"groupId": "BG003", "value": "243"}]}]}, {"title": "Ethnicity: Non Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "121"}, {"groupId": "BG001", "value": "159"}, {"groupId": "BG002", "value": "157"}, {"groupId": "BG003", "value": "437"}]}]}]}, {"title": "Glycosylated Hemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.06", "spread": "0.90"}, {"groupId": "BG001", "value": "8.04", "spread": "0.86"}, {"groupId": "BG002", "value": "8.09", "spread": "0.91"}, {"groupId": "BG003", "value": "8.06", "spread": "0.89"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "millimole per liter (mmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.51", "spread": "2.28"}, {"groupId": "BG001", "value": "9.43", "spread": "2.15"}, {"groupId": "BG002", "value": "9.31", "spread": "2.25"}, {"groupId": "BG003", "value": "9.40", "spread": "2.22"}]}]}]}, {"title": "2-hour Postprandial Plasma Glucose (PPG)", "description": "Number of patients analyzed = 169, 253 and 252 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15.51", "spread": "3.43"}, {"groupId": "BG001", "value": "15.62", "spread": "3.97"}, {"groupId": "BG002", "value": "15.46", "spread": "4.03"}, {"groupId": "BG003", "value": "15.53", "spread": "3.86"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.15", "spread": "20.14"}, {"groupId": "BG001", "value": "90.09", "spread": "21.10"}, {"groupId": "BG002", "value": "89.05", "spread": "20.74"}, {"groupId": "BG003", "value": "89.71", "spread": "20.70"}]}]}]}, {"title": "Homeostasis Model Assessment for Beta-cell Function (HOMA-beta)", "description": "Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (fasting plasma glucose \\[mmol/L\\] minus 3.5). Number of patients analyzed = 168, 251 and 252 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of normal beta cells function", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.48", "spread": "42.12"}, {"groupId": "BG001", "value": "42.82", "spread": "32.33"}, {"groupId": "BG002", "value": "45.21", "spread": "46.09"}, {"groupId": "BG003", "value": "43.38", "spread": "40.38"}]}]}]}, {"title": "Adiponectin", "description": "Number of patients analyzed = 164, 248 and 248 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "microgram per milliliter (mcg/mL)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.61", "spread": "3.26"}, {"groupId": "BG001", "value": "5.25", "spread": "2.90"}, {"groupId": "BG002", "value": "5.25", "spread": "2.93"}, {"groupId": "BG003", "value": "5.34", "spread": "3.01"}]}]}]}, {"title": "Fasting Plasma Insulin (FPI)", "description": "Number of patients analyzed = 168, 251 and 253 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "picomole per liter (pmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "75.79", "spread": "48.02"}, {"groupId": "BG001", "value": "83.68", "spread": "63.60"}, {"groupId": "BG002", "value": "77.90", "spread": "65.46"}, {"groupId": "BG003", "value": "79.53", "spread": "60.84"}]}]}]}, {"title": "2-hour Postprandial Plasma Insulin (PPI)", "description": "Number of patients analyzed = 151, 232 and 240 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "374.28", "spread": "266.55"}, {"groupId": "BG001", "value": "380.53", "spread": "260.96"}, {"groupId": "BG002", "value": "378.67", "spread": "328.19"}, {"groupId": "BG003", "value": "378.30", "spread": "289.51"}]}]}]}, {"title": "Fasting C-peptide", "description": "Number of patients analyzed = 164, 252 and 249 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "nanomole per liter (nmol/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.90", "spread": "0.36"}, {"groupId": "BG001", "value": "0.97", "spread": "0.43"}, {"groupId": "BG002", "value": "0.94", "spread": "0.43"}, {"groupId": "BG003", "value": "0.94", "spread": "0.41"}]}]}]}, {"title": "2-hour Postprandial C-peptide", "description": "Number of patients analyzed = 166, 251 and 249 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "nmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.46", "spread": "1.08"}, {"groupId": "BG001", "value": "2.56", "spread": "1.11"}, {"groupId": "BG002", "value": "2.42", "spread": "1.16"}, {"groupId": "BG003", "value": "2.48", "spread": "1.12"}]}]}]}, {"title": "Fasting Glucagon", "description": "Number of patients analyzed = 162, 242 and 247 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "nanogram per liter (ng/L)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "87.92", "spread": "29.05"}, {"groupId": "BG001", "value": "88.89", "spread": "32.90"}, {"groupId": "BG002", "value": "88.53", "spread": "27.30"}, {"groupId": "BG003", "value": "88.51", "spread": "29.88"}]}]}]}, {"title": "2-hour Postprandial Glucagon", "description": "Number of patients analyzed = 163, 241 and 248 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "101.30", "spread": "33.88"}, {"groupId": "BG001", "value": "101.46", "spread": "34.54"}, {"groupId": "BG002", "value": "100.90", "spread": "34.12"}, {"groupId": "BG003", "value": "101.21", "spread": "34.17"}]}]}]}, {"title": "Fasting Proinsulin", "description": "Number of patients analyzed = 142, 223 and 226 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.68", "spread": "20.10"}, {"groupId": "BG001", "value": "34.93", "spread": "24.14"}, {"groupId": "BG002", "value": "32.35", "spread": "18.45"}, {"groupId": "BG003", "value": "33.16", "spread": "21.16"}]}]}]}, {"title": "2-hour Postprandial Proinsulin", "description": "Number of patients analyzed = 139, 204 and 213 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "83.48", "spread": "58.02"}, {"groupId": "BG001", "value": "83.71", "spread": "54.65"}, {"groupId": "BG002", "value": "77.19", "spread": "53.44"}, {"groupId": "BG003", "value": "81.15", "spread": "55.05"}]}]}]}, {"title": "Glucose Excursion", "description": "Number of patients analyzed = 168, 252 and 252 for Placebo (Combined), Lixisenatide (Morning Injection) and Lixisenatide (Evening Injection) treatment arms, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.64", "spread": "2.81"}, {"groupId": "BG001", "value": "6.09", "spread": "3.09"}, {"groupId": "BG002", "value": "5.80", "spread": "3.13"}, {"groupId": "BG003", "value": "5.87", "spread": "3.04"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "BMI was calculated by dividing body weight by the height squared.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilogram per square meter (kg/m^2)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.12", "spread": "6.45"}, {"groupId": "BG001", "value": "33.22", "spread": "6.85"}, {"groupId": "BG002", "value": "32.47", "spread": "5.77"}, {"groupId": "BG003", "value": "32.91", "spread": "6.36"}]}]}]}, {"title": "Duration of Diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.87", "spread": "4.72"}, {"groupId": "BG001", "value": "6.18", "spread": "5.25"}, {"groupId": "BG002", "value": "6.21", "spread": "5.40"}, {"groupId": "BG003", "value": "6.11", "spread": "5.17", "lowerLimit": "0.8", "upperLimit": "52.1"}]}]}]}, {"title": "Duration of Metformin Treatment", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.34", "spread": "3.45"}, {"groupId": "BG001", "value": "3.73", "spread": "3.34"}, {"groupId": "BG002", "value": "3.68", "spread": "3.90"}, {"groupId": "BG003", "value": "3.61", "spread": "3.59"}]}]}]}, {"title": "Metformin Daily Dose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milligram (mg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2001.18", "spread": "439.70"}, {"groupId": "BG001", "value": "1968.82", "spread": "446.99"}, {"groupId": "BG002", "value": "1942.65", "spread": "406.17"}, {"groupId": "BG003", "value": "1967.10", "spread": "430.22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in Modified Intent-to-treat (mITT) population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "244"}, {"groupId": "OG002", "value": "239"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.075"}, {"groupId": "OG001", "value": "-0.87", "spread": "0.065"}, {"groupId": "OG002", "value": "-0.75", "spread": "0.066"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To detect 0.5%(or 0.4%) difference between 1 lixisenatide arm and placebo(combined), 225 patients in lixisenatide arm, 170 in placebo(combined) would provide a power of 97% (or 87%) assuming common standard deviation=1.3% with 2-sided test at 5% significance. Statistical testing:2-sided at significance level=0.05. Analysis of co-variance(ANCOVA)included treatment arms, randomization strata of screening HbA1c(\\<8.0,\\>=8.0%),BMI(\\<30,\\>=30 kg/m\\^2),country as fixed effects, baseline HbA1c as covariate.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Stepwise testing procedure applied to control type 1 error: lixisenatide (morning) compared with placebo (combined), if found statistically significant, then lixisenatide (evening) compared with placebo (combined).", "statisticalMethod": "ANCOVA", "paramType": "Least squares (LS) mean difference", "paramValue": "-0.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.657", "ciUpperLimit": "-0.312", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.088"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "To detect 0.5%(or 0.4%) difference between 1 lixisenatide arm and placebo(combined), 225 patients in lixisenatide arm, 170 in placebo(combined) would provide a power of 97% (or 87%) assuming common standard deviation=1.3% with 2-sided test at 5% significance. Statistical testing:2-sided at significance level=0.05. Analysis of co-variance(ANCOVA)included treatment arms, randomization strata of screening HbA1c(\\<8.0,\\>=8.0%),BMI(\\<30,\\>=30 kg/m\\^2),country as fixed effects, baseline HbA1c as covariate.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Stepwise testing procedure applied to control type 1 error: lixisenatide (morning) compared with placebo (combined), if found statistically significant, then lixisenatide (evening) compared with placebo (combined).", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.540", "ciUpperLimit": "-0.193", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.088"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using last observation carried forward (LOCF). Here, number of patients analyzed = patients with baseline and at least 1 post-baseline FPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "253"}, {"groupId": "OG002", "value": "255"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "0.166"}, {"groupId": "OG001", "value": "-1.19", "spread": "0.145"}, {"groupId": "OG002", "value": "-0.81", "spread": "0.146"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) at Week 24", "description": "The 2-hour PPG test measured blood glucose 2 hours after eating a standardized meal. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline 2-hour PPG assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.41", "spread": "0.588"}, {"groupId": "OG001", "value": "-5.92", "spread": "0.415"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilogram", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.64", "spread": "0.269"}, {"groupId": "OG001", "value": "-2.01", "spread": "0.234"}, {"groupId": "OG002", "value": "-2.02", "spread": "0.236"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline plasma insulin assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "237"}, {"groupId": "OG002", "value": "229"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.23", "spread": "3.254"}, {"groupId": "OG001", "value": "-5.09", "spread": "2.812"}, {"groupId": "OG002", "value": "-1.88", "spread": "2.862"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial Plasma Insulin (PPI) at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to the last dosing day of the study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline PPI assessment during on-treatment period", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-25.67", "spread": "38.028"}, {"groupId": "OG001", "value": "-87.24", "spread": "24.885"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Proinsulin at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.78", "spread": "2.246"}, {"groupId": "OG001", "value": "-7.78", "spread": "1.414"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial Proinsulin at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline proinsulin assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.83", "spread": "5.253"}, {"groupId": "OG001", "value": "-18.88", "spread": "3.406"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting C-Peptide at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "0.031"}, {"groupId": "OG001", "value": "-0.10", "spread": "0.020"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial C-Peptide at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline C-peptide assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "193"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.20", "spread": "0.137"}, {"groupId": "OG001", "value": "-0.46", "spread": "0.097"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Glucose Excursion at Week 24", "description": "Glucose excursion = 2-hour PPG minus plasma glucose 30 minutes prior to the standardized meal test, before study drug administration. Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal teat. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucose excursion assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "198"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.76", "spread": "0.483"}, {"groupId": "OG001", "value": "-4.64", "spread": "0.340"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Glucagon at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.53", "spread": "3.054"}, {"groupId": "OG001", "value": "-13.27", "spread": "2.074"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-Hour Postprandial Glucagon at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to last dosing day of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy.", "populationDescription": "Subgroup for standardized meal test (patients from morning injection arms only) as pre-specified in the protocol. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline glucagon assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/L", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo to lixisenatide."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.79", "spread": "3.551"}, {"groupId": "OG001", "value": "-27.04", "spread": "2.467"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Adiponectin at Week 24", "description": "Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline adiponectin assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mcg/mL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "236"}, {"groupId": "OG002", "value": "227"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.54", "spread": "0.183"}, {"groupId": "OG001", "value": "0.55", "spread": "0.159"}, {"groupId": "OG002", "value": "0.58", "spread": "0.160"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24", "description": "Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (FPG \\[mmol/L\\] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Missing data was imputed using LOCF. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HOMA-beta assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "% of normal beta cells function", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "235"}, {"groupId": "OG002", "value": "226"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.16", "spread": "2.823"}, {"groupId": "OG001", "value": "7.96", "spread": "2.450"}, {"groupId": "OG002", "value": "4.80", "spread": "2.486"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Patients With at Least 5% Weight Loss From Baseline at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline body weight assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation, morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "248"}, {"groupId": "OG002", "value": "249"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.3"}, {"groupId": "OG001", "value": "14.9"}, {"groupId": "OG002", "value": "19.3"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Patients With Symptomatic Hypoglycemia and Severe Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available.", "populationDescription": "Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First dose of study drug up to 3 days after the last dose administration", "groups": [{"id": "OG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo."}, {"id": "OG001", "title": "Placebo (Evening Injection)", "description": "2-step initiation evening regimen of volume matching placebo."}, {"id": "OG002", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation, morning and evening regimen of volume matching placebo."}, {"id": "OG003", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG004", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}, {"id": "OG005", "title": "Lixisenatide (Combined)", "description": "Included all patients who received 2-step initiation, morning and evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "170"}, {"groupId": "OG003", "value": "255"}, {"groupId": "OG004", "value": "255"}, {"groupId": "OG005", "value": "510"}]}], "classes": [{"title": "Symptomatic Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "18"}, {"groupId": "OG004", "value": "22"}, {"groupId": "OG005", "value": "40"}]}]}, {"title": "Severe Symptomatic Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Requiring Rescue Therapy During the Main 24-Week Period", "description": "Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "255"}, {"groupId": "OG002", "value": "255"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.6"}, {"groupId": "OG001", "value": "2.7"}, {"groupId": "OG002", "value": "3.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "244"}, {"groupId": "OG002", "value": "239"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.0"}, {"groupId": "OG001", "value": "43.0"}, {"groupId": "OG002", "value": "40.6"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than or Equal to 6.5% at Week 24", "description": "The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.", "populationDescription": "mITT population. Here, number of patients analyzed = patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo."}, {"id": "OG001", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide."}, {"id": "OG002", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "244"}, {"groupId": "OG002", "value": "239"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.4"}, {"groupId": "OG001", "value": "23.8"}, {"groupId": "OG002", "value": "19.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First dose of study drug up to 3 days after the last dose administration", "description": "Median exposure to study treatment were 564, 561.5 and 567.5 days for the morning lixisenatide, evening lixisenatide combined placebo treatment arms, respectively.The analysis was performed on safety population, defined as all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.", "eventGroups": [{"id": "EG000", "title": "Placebo (Morning Injection)", "description": "2-step initiation morning regimen of volume matching placebo.", "seriousNumAffected": 2, "seriousNumAtRisk": 85, "otherNumAffected": 45, "otherNumAtRisk": 85}, {"id": "EG001", "title": "Placebo (Evening Injection)", "description": "2-step initiation evening regimen of volume matching placebo.", "seriousNumAffected": 9, "seriousNumAtRisk": 85, "otherNumAffected": 50, "otherNumAtRisk": 85}, {"id": "EG002", "title": "Placebo (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of volume matching placebo.", "seriousNumAffected": 11, "seriousNumAtRisk": 170, "otherNumAffected": 95, "otherNumAtRisk": 170}, {"id": "EG003", "title": "Lixisenatide (Morning Injection)", "description": "2-step initiation morning regimen of lixisenatide.", "seriousNumAffected": 21, "seriousNumAtRisk": 255, "otherNumAffected": 182, "otherNumAtRisk": 255}, {"id": "EG004", "title": "Lixisenatide (Evening Injection)", "description": "2-step initiation evening regimen of lixisenatide.", "seriousNumAffected": 26, "seriousNumAtRisk": 255, "otherNumAffected": 169, "otherNumAtRisk": 255}, {"id": "EG005", "title": "Lixisenatide (Combined)", "description": "Included all patients who received 2-step initiation morning and evening regimen of lixisenatide.", "seriousNumAffected": 47, "seriousNumAtRisk": 510, "otherNumAffected": 351, "otherNumAtRisk": 510}], "seriousEvents": [{"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Bacterial sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Escherichia urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 510}]}, {"term": "Staphylococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Signet-ring cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Thyroid neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Psychosomatic disease", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Carpal tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Hypertensive encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Lacunar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Ruptured cerebral aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Retinal haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Vitreous haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 510}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 510}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Atrioventricular block first degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 510}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Bronchial obstruction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Abdominal adhesions", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Gastric haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Inguinal hernia, obstructive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Rectal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 510}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Necrobiosis", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Pancreatic enzymes increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Dislocation of vertebra", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 510}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Skull fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Spinal cord injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Cardiac pacemaker insertion", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}, {"term": "Coronary artery bypass", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 510}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 22, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 28, "numAtRisk": 510}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 12, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 26, "numAtRisk": 510}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 30, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 28, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 58, "numAtRisk": 510}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 26, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 38, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 20, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 58, "numAtRisk": 510}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 16, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 22, "numAtRisk": 510}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 22, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 15, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 37, "numAtRisk": 510}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 10, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 25, "numAtRisk": 510}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Hypoglycaemia adverse event is based on investigator reported hypoglycaemia.", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 23, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 28, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 51, "numAtRisk": 510}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 18, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 14, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 32, "numAtRisk": 510}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 28, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 49, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 42, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 91, "numAtRisk": 510}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 15, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 32, "numAtRisk": 510}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 19, "numAtRisk": 510}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 20, "numAtRisk": 510}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 10, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 21, "numAtRisk": 510}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 39, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 36, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 75, "numAtRisk": 510}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 13, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 28, "numAtRisk": 510}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 64, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 63, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 127, "numAtRisk": 510}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 35, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 40, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 75, "numAtRisk": 510}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 18, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 27, "numAtRisk": 510}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 21, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 21, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 42, "numAtRisk": 510}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 23, "numAtRisk": 510}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 18, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 12, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 30, "numAtRisk": 510}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 85}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 85}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 255}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 255}, {"groupId": "EG005", "numAffected": 23, "numAtRisk": 510}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-us@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}